Caris Life Sciences, Inc. CAI
Caris Life Sciences, Inc. (Nasdaq: CAI) is an oncology diagnostics company. Its next catalyst on record is Caris Assure for Therapy Selection: Submit to NY CLEP (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Caris Assure for Therapy Selection — Submit to NY CLEP (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MI Profile / MI Cancer Seek (WES/WTS tissue; PMA-approved companion diagnostic) | Tumor profiling / companion diagnostic | unclear | NA_NON_THERAPEUTIC |
| Caris Assure (blood WES/WTS) for therapy selection | Therapy selection, MRD, monitoring | unclear | NA_NON_THERAPEUTIC |
| Caris Detect (multi-cancer early detection) | Multi-cancer early detection | unclear | NA_NON_THERAPEUTIC |
| Caris ChromoSeq | Myeloid malignancies | unclear | NA_NON_THERAPEUTIC |
| Caris MI Clarity | Breast cancer recurrence-risk prognostic | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Guardant Health, Inc. GH
- GRAIL, Inc. GRAL
- NovoCure Ltd NVCR
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Freenome, Inc. FRNM
- Alpha Tau Medical Ltd. DRTS
- Castle Biosciences Inc CSTL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.